Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma

    Research output: Contribution to journalReviewResearchpeer-review

  2. Outcome of an enhanced diagnostic pipeline for patients suspected of inherited thrombocytopenia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
The treatment of chronic lymphocytic leukaemia (CLL) has been improved by introduction of monoclonal antibodies (mAbs) that exert their effect through secondary effector mechanisms. CLL cells are characterized by expression of CD5 and CD23 along with CD19 and CD20, hence anti-CD5 Abs that engage secondary effector functions represent an attractive opportunity for CLL treatment. Here, a repertoire of mAbs against human CD5 was generated and tested for ability to induce complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) both as single mAbs and combinations of two mAbs against non-overlapping epitopes on human CD5. The results demonstrated that combinations of two mAbs significantly increased the level of CDC compared to the single mAbs, while no enhancement of ADCC was seen with anti-CD5 mAb combinations. High levels of CDC and ADCC correlated with low levels of Ab-induced CD5 internalization and degradation. Importantly, an anti-CD5 mAb combination enhanced CDC of CLL cells when combined with the anti-CD20 mAbs rituximab and ofatumumab as well as with the anti-CD52 mAb alemtuzumab. These results suggest that an anti-CD5 mAb combination inducing CDC and ADCC may be effective alone, in combination with mAbs against other targets or combined with chemotherapy for CLL and other CD5-expressing haematological or lymphoid malignancies.
Original languageEnglish
JournalBritish Journal of Haematology
Volume163
Issue number2
Pages (from-to)182-93
Number of pages12
ISSN0007-1048
DOIs
Publication statusPublished - Oct 2013

    Research areas

  • Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antibody-Dependent Cell Cytotoxicity, Antigens, CD20, Antigens, CD5, Cell Line, Tumor, Cell Survival, Chromosome Aberrations, Complement System Proteins, Cytotoxicity, Immunologic, Drug Synergism, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged

ID: 42572696